Simplify Logo

Full-Time

Engineer I

Upstream Development for Protein Development & Manufacturing

Posted on 6/18/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Hardware
Biotechnology

Compensation Overview

$74k - $90kAnnually

+ Equity

Expert

San Carlos, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Chemical Engineering or related discipline with 5+ years of relevant Pharma/Biotech industry experience, or MS in Chemical Engineering with 10+ years of relevant Pharma/Biotech industry experience
  • Strong background in cell-free protein synthesis
  • Hands-on experience with CFPS and primary recovery unit operations
  • Good understanding of bioreactor design, operation, and controls
  • Strong knowledge of aseptic techniques
  • Mechanical and technical knowledge of primary recovery unit operations such as centrifugation and depth filtration is a plus
  • Familiarity with DoE (Design of Experiments) principles and software
  • Familiarity with regulatory requirements of biotherapeutics. Late-stage process characterization experience is a plus
Responsibilities
  • Develop, test, and implement recipe scripting for CFPS
  • Provide engineering support for selection, commissioning, and qualification of new CFPS-related equipment as well as scale-down models
  • Design and execution of upstream CFPS experiments in various platforms including plate-based assays and SUB pilot bioreactors
  • Author SOPs, process flow diagrams, and batch records
  • Analyze and present CFPS data at internal project meetings
  • Participate in upstream database management and documentation in electronic notebooks
  • Develop CFPS scale-up/down models to support technology transfer and manufacturing activities
  • Knowledge of ambr-250 bioreactor system a plus

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to protect vulnerable populations from serious bacterial infections.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

53%

2 year growth

114%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.
INACTIVE